Clinical Reviews in Allergy & Immunology

, Volume 37, Issue 2, pp 114–124

Factor VIII Inhibitors: Risk Factors and Methods for Prevention and Immune Modulation

  • Ai Hong Zhang
  • Jonathan Skupsky
  • David W. Scott
Article

DOI: 10.1007/s12016-009-8122-5

Cite this article as:
Zhang, A.H., Skupsky, J. & Scott, D.W. Clinic Rev Allerg Immunol (2009) 37: 114. doi:10.1007/s12016-009-8122-5

Abstract

Patients with hemophilia A are deficient in coagulation Factor VIII. This bleeding disorder can be treated with Factor VIII replacement therapy, but close to a third of patients will be immunized to the treatment and begin to form inhibitory antibodies known as “inhibitors”. These inhibitors will render the treatment ineffective and represent the most severe complication in the treatment of hemophilia A. In this review, we highlight factors involved in inhibitor development and emphasize research being done to modulate the immune response to this life-saving therapy.

Keywords

Hemophilia inhibitors Immunogenicity Immune tolerance FVIII 

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Ai Hong Zhang
    • 1
  • Jonathan Skupsky
    • 1
  • David W. Scott
    • 1
  1. 1.Departments of Surgery and of Microbiology and Immunology, and Center for Vascular and Inflammatory DiseasesUniversity of Maryland School of MedicineBaltimoreUSA

Personalised recommendations